Global Peptide Therapeutics Market Report 2026: Market Is Projected To Surpass US$ 60 Billion By 2026

/EIN News/ -- Dublin, Jan. 09, 2020 (GLOBE NEWSWIRE) -- The "Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Over the last several decades, therapeutic peptides and proteins have risen as a potential drug candidate. Many companies are specializing in their manufacturing, along with companies developing peptide-based products ranging from new drug candidates to medical diagnostic devices. The massive increase in the cost and time span to develop a conventional drug led researchers and pharmaceutical companies to develop new cost-effective products based of synthetic peptide strategy, which led to development large number of peptides of medical importance.

The lower toxicity levels of peptides can be credited to both their lower instance of interaction with other molecules not of interest and also to their ease of metabolism into their component amino acid residues. Pharmaceutical companies are attracted towards the peptides due to ease of manufacturing. In contrast to the old trial and error routines, nowadays the process starts with a clear understanding of the disease on a molecular level and based over the hypotheses of drug outcome, new drugs are designed.

The necessity of peptides as new innovative drug development has also been raised by the property of peptides being bioactive as considered one of the major interests of pharmaceuticals. As compared to synthetic substances peptides degrade into their component proteinogenic amino acid without leading to toxic metabolites. Furthermore, a disadvantage can sometimes be an advantage as peptides possess short half-lives which make them costly on one hand but the advantage is less accumulation in the body.

"Global Peptide Drug Market Is Projected To Surpass US$ 60 Billion By 2026 Driven By Strong Clinical Pipeline & Favorable Commercialization Parameters"

In reference to these favourable attributes, the peptide drug market is flourishing and several peptide-based therapeutics have been commercialized. With enhanced technologies, the prospects of the peptide drugs are getting influential day by day and new peptides are being discovered to be developed as peptide drug. Peptide therapeutics is completely different from the traditional way and may open a new window for finding completely new peptide drugs. Also, bioinformatics and systematic biological approaches help in searching for potential peptide drug candidates based on the knowledge and data.

The future potential of expanding peptide therapeutics market is contributed towards the characteristics like safety, targeted drug delivery and high specificity. Especially for illnesses requiring prolonged therapy, peptides have a competitive advantage over conventional small molecule drugs. Due to their extremely high specificity for their intended target, in combination with the fact that they are extra cellularly active, much lower amounts can be formulated.

Key Topics Covered:

• Introduction to Peptide Therapeutics
  
• Foundation of Peptide Therapeutics
  
• Key Aspects in Peptide Drug Development
  
• Peptide Therapeutics over Traditional Molecules
  
• Global Peptide Therapeutics Market Scenario
  
• Global Peptide Oncology Thereupetics Market Scenario
  
• Cancer Peptides Drug Cost, Dosage & Patent Insight
  
• Peptide Therapeutics in Cardiovascular Disease
  
• Peptide Therapeutics in Metabolic Disorder
  
• Peptide Therapeutics For Infections
  
• Peptide Therapeutics aganist CNS Disorders
  
• Global Peptides Drug Clinical Insight by Type
  
• Global Peptide Drug Market Dynamics - Challenges & Drivers
  
• Global Peptide Therapeutics Market Future Panorama
  
• Oligopeptides Clinical Pipeline By Company, Indication & Phase
  
• Insulin Clinical Pipeline By Company, Indication & Phase
  
• Peptide Hormone Clinical Pipeline By Company, Indication & Phase
  
• Peptide Clinical Pipeline By Company, Indication & Phase
  
• Glucagon-Like Peptide Clinical Pipeline By Company, Indication & Phase
  
• Glycopeptide Clinical Pipeline By Company, Indication & Phase
  
• Multiple Peptide Clinical Pipeline By Company, Indication & Phase
  
• Peptide vaccine Clinical Pipeline By Company, Indication & Phase
  
• Cyclic Peptide Clinical Pipeline By Company, Indication & Phase
  
• Peptide Fragment Clinical Pipeline By Company, Indication & Phase
  
• Dipeptide Clinical Pipeline By Company, Indication & Phase
  
• Opioid peptide Clinical Pipeline By Company, Indication & Phase
  
• Depsipeptide Clinical Pipeline By Company, Indication & Phase
  
• Natriuretic Peptide Clinical Pipeline By Company, Indication & Phase
  
• Neuropeptide Clinical Pipeline By Company, Indication & Phase
  
• Pituitary Gonadotropin Clinical Pipeline By Company, Indication & Phase
  
• Lipopeptide Clinical Pipeline By Company, Indication & Phase
  
• Peptide Aptamer Clinical Pipeline By Company, Indication & Phase
  
• Competitive Landscape
  

Companies Mentioned

• Amgen
• Amylin Pharmaceuticals
• Apitope Technology
• BioPartners
• BiondVax Pharmaceuticals Ltd
• Boehringer Ingelheim
• Circassia
• Corden Pharma (Peptisyntha)
• Eli Lily
• Galena Biopharmaceuticals
• GlaxoSmithKline
• Hyperion Therapeutics
• ImmunoCellular Therapeutics
• Ipsen
• Lonza
• Merck
• NovoNordisk
• Par Pharmaceuticals
• PeptiDream
• Roche
• Sanofi
• Tarix Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/gepoyd

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900